Nitrile SUMO Inhibitors for Selective E1 Enzyme Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aberrations in post-translational modification of cellular proteins by the small ubiquitin-like modifier (SUMO) family of proteins contribute to the pathogenesis of life-threatening diseases such as cancer, neurodegenerative disorders, and viral infection, necessitating the development of therapeutics targeting the E1 enzyme.
Innovation Solution
Development of compounds that inhibit the E1 enzyme, specifically those with structures defined by certain ring systems and substituents, to regulate SUMO-modification and potentially treat these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment options are limited, but effective inhibition of E1 enzyme is not achieved
Solution Approach 1:
The patent modifies molecular parameters by designing compounds with specific structural features (Formula I-V) that enable covalent binding to the E1 enzyme's catalytic cysteine residue. This structural parameter change transforms the compounds into effective E1 inhibitors, resolving the contradiction between limited therapeutic options and need for targeted agents.
2Productivity
If E1 enzyme activity is inhibited, then cancer cell proliferation is reduced, but specificity of inhibition must be maintained
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target the catalytic cysteine residue (Cys30 of Uba2 subunit 2) of the E1 enzyme. The molecular structure incorporates local functional groups that recognize and bind to this specific residue, ensuring selective inhibition of E1 enzyme activity while maintaining specificity, thereby reducing cancer cell proliferation without off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit the E1 enzyme, offering a therapeutic approach to modulate SUMO-modification and address the underlying mechanisms of these diseases.
Implementation Method 1
compounds that covalently bind to the E1 cysteine amino acid corresponding to Cys30 of the Uba2 subunit 2, inhibiting the E1 enzyme's activity
Data Source
AI summary
The present invention relates to cyano-containing compounds and compositions capable of acting as inhibitors of small ubiquitin-like modifier (SUMO) family of proteins. The compounds and compositions may be used in the treatment of cancer. There are disclosed, inter alia, methods of inhibiting an E1 enzyme, and compounds useful for inhibiting an E1 enzyme.